Избранные публикации за 5 лет

1. Shevtsov M, Stangl S, Nikolaev B, Yakovleva L, Marchenko Y, Tagaeva R, Sievert W, Pitkin E, Mazur A, Toltoy P, Galibin O, Ryzhov V, Steiger K, Smirnov O, Khachatryan W, Chester K, Multhoff G. Granzyme B functionalized nanoparticles targeting membrane Hsp70-positive tumors for multimodal cancer theranostics. Small. 2019; 15(13):e1900205. WoS IF = 10.856, Q1

2. Shevtsov M, Sato H, Multhoff G, Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. Frontiers in Oncology. 2019;9:156. WoS IF = 4.25, Q1

3. Shevtsov M, Pitkin E, Ischenko A, Stangl S, Khachatryan W, Galibin O, Edmond S, Lobinger D, Multhoff G. Ex vivo Hsp70-activated NK cells in combination with PD‑1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Frontiers in Immunology. 2019;10:454. WoS IF = 4.716, Q1

4. Stangl S, Tei L, De-Rose F, Reder S, Martinelli J, Sievert W, Shevtsov M, Öllinger R, Rad R, Schwaiger M, Alessandria CD, Multhoff G. Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[89Zr] for tumor-specific PET/CT imaging. Cancer Research. 2018;78(21):6268–628. WoS IF = 8.378, Q1

5. Shevtsov M, Nikolaev B, Marchenko Y, Yakovleva L, Skvorzov N, Mazur A, Tolstoy P, Ryzhov V, Multhoff G. Targeting experimental glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs). International Journal of Nanomedicine. 2018;13:1471–1482. WoS IF = 4.471, Q1

6. Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Schmid TE, Pigorsch S, Combs SE, Haller B, Balermpas P, Rödel F, Rödel C, Fokas E, Krause M, Linge A, Lohhaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Maihöfer C, Mönnich D, Zips D, Multhoff G. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer. 2018;142(9):1911–1925. WoS IF = 4.982, Q1

7. Shevtsov MA, Parr MA, Ryzhov VA, Zemtsova EG, Ponomareva AN, Smirnov VM, Multhoff G. Zero-valent Fe confined mesoporous silica nanoparticles (Fe(0)@MCM-41) for targeting experimental orthotopic glioma in rats. Scientific Reports. 2016;6:29247. WoS IF = 4.011, Q1

8. Shevtsov MA, Nikolaev BP, Ryzhov VA, Yakovleva LY, Marchenko YY, Parr MA, Rolich VI, Mikhrina AL, Dobrodumov AV, Pitkin E, Multhoff G. Ionizing radiation improves glioma-specific targeting of superparamagnetic iron oxide nanoparticles conjugated with cmHsp70.1 antibodies (SPION-cmHsp70.1). Nanoscale. 2015;7(48):20652–20664. WoS IF = 6.970, Q1

9. Shevtsov MA, Nikolaev BP, Yakovleva LY, Parr MA, Marchenko YY, Eliseev I, Dobrodumov AV, Zlobina O, Zhakhov A, Ischenko AM, Pitkin E, Multhoff G. 70-kDa heat shock protein coated magnetic nanoparticles as a nanovaccine for induction of anti-tumor immune response in experimental glioma. Journal of Controlled Release. 2015 Oct29;220(PtA):329–340. WoS IF = 7.901, Q1

10. Shevtsov MA, Nikolaev BP, Yakovleva LY, Dobrodumov AV, Zhakhov AV, Mikhrina AL, Pitkin E, Parr MA, Rolich VI, Simbircev AS, Ischenko AM. Recombinant interleukin‑1 receptor antagonist conjugated to superparamagnetic iron oxide nanoparticles for theranostic targeting of experimental glioblastoma. Neoplasia. 2015;17(1):32–42. WoS IF = 3.837, Q1